JP Morgan Put 430 VRTX 17.01.2025/ DE000JK10UQ8 /
07/06/2024 16:06:49 | Chg.-0.06 | Bid22:00:44 | Ask22:00:44 | Underlying | Strike price | Expiration date | Option type |
---|---|---|---|---|---|---|---|
1.81EUR | -3.21% | - Bid Size: - |
- Ask Size: - |
Vertex Pharmaceutica... | 430.00 USD | 17/01/2025 | Put |
GlobeNewswire
15/05
Third Harmonic Bio Announces First Quarter 2024 Financial Results and Provides Business Update
GlobeNewswire
09/05
CRISPR Therapeutics to Present at the Bank of America Securities Health Care Conference
GlobeNewswire
08/05
CRISPR Therapeutics Provides Business Update and Reports First Quarter 2024 Financial Results
GlobeNewswire
08/05
CRISPR Therapeutics Highlights ASGCT Oral Presentation and Announces New Programs Utilizing In Vivo ...
GlobeNewswire
07/05
Prelude Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update
GlobeNewswire
30/04
American Kidney Fund Encourages People to Be APOL1 Aware with First Annual APOL1-Mediated Kidney Dis...
GlobeNewswire
27/04
SHAREHOLDER INVESTIGATION NOTICE: Halper Sadeh LLC Investigates MODN, AIRC, INRD, ALPN
GlobeNewswire
22/04
TAKE ACTION: The M&A Class Action Firm Launches Legal Inquiry for the Merger - ALPN, LABP, SWAV, FUS...
GlobeNewswire
22/04
CRISPR Therapeutics to Present Oral Presentation at the American Society of Gene & Cell Therapy (ASG...
GlobeNewswire
09/04
American Kidney Fund and Alonzo Mourning Call for More Awareness and Understanding of APOL1-Mediated...
GlobeNewswire
03/04
CRISPR Therapeutics to Present at the Annual Needham Virtual Healthcare Conference
GlobeNewswire
01/04
CervoMed Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Updates
GlobeNewswire
01/04
CRISPR Therapeutics to Present at the American Society of Gene & Cell Therapy (ASGCT) 2024 Annual Me...
GlobeNewswire
15/03
American Kidney Fund Announces 2024 Class of Corporate Members Providing Support in the Fight Agains...
GlobeNewswire
13/03
Entrada Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results